Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
NCT07481747 on ClinicalTrials.gov · last registry update 2026-03-19
An unusually large phase 3: 2,539 participants, more than double the 424 typical for the stage. Due to report 14 February 2027, alongside 30 other tracked readouts that quarter. Primary outcome, as filed: Mean percent change in body weight from randomization. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P3
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- Hudson Biotech
- Sponsor type
- Industry
- Enrollment
- 2,539
- Started
- 2026-02-02
- Primary completion
- 2027-02-14 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Mean percent change in body weight from randomization
Conditions studied
Obesity · Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.